1-9 of 9
Eyal Lebel
Close
Sort by
Journal Articles

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Eyal Lebel, Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky, Moshe E Gatt
Journal: Blood
Blood (2023) 142 (Supplement 1): 538.
https://doi.org/10.1182/blood-2023-186450
Published: 2023
Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit
Journal: Blood
Blood (2023) 142 (Supplement 1): 341.
https://doi.org/10.1182/blood-2023-190178
Published: 2023
Journal Articles

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Arnon Haran, Noa Gros Even-Zohar, Eyal Lebel, Shlomzion Aumann, Adir Shaulov, Moshe E Gatt, Boaz Nachmias
Journal: Blood
Blood (2023) 142 (Supplement 1): 6277.
https://doi.org/10.1182/blood-2023-187241
Published: 2023
Journal Articles

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Moshe E Gatt, Polina Stepensky
Journal: Blood
Blood (2023) 142 (Supplement 1): 4852.
https://doi.org/10.1182/blood-2023-185069
Published: 2023
Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt
Journal: Blood
Blood (2023) 142 (Supplement 1): 6763.
https://doi.org/10.1182/blood-2023-173317
Published: 2023
Journal Articles

Tecam (Thiotepa, Etoposide, cyclophosphamide, Cytarabine and Melphalan) Is an Effective and Safe Conditioning Regimen for Autologous Transplant in Lymphoma

Yarden Cohen, Eyal Lebel, Eran Zimran, Adir Shaulov, Polina Stepensky, Sigal Grisariu Greenzaid, Batia Avni
Journal: Blood
Blood (2022) 140 (Supplement 1): 4859–4860.
https://doi.org/10.1182/blood-2022-165401
Published: 2022
Journal Articles

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna E. Reece, Suzanne Trudel, Rodger E Tiedemann, Anca Prica, Vishal Kukreti, Christine I. Chen
Journal: Blood
Blood (2021) 138 (Supplement 1): 1837.
https://doi.org/10.1182/blood-2021-151862
Published: 2021
Journal Articles

Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma

Eyal Lebel, Neta Goldschmidt, Tali Siegal, MD, Alexander Lossos, MD, Moshe Gatt, MD, Alexander Gural, MD, Adir Shaulov, MD, Revital Saban, MD, David Lavie, MD, Boaz Nachmias, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–49.
https://doi.org/10.1182/blood-2020-140949
Published: 2020
Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer
Journal: Blood
Blood (2017) 130 (Supplement 1): 1563.
https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563
Published: 2017